Journal of Medicinal Chemistry · 2013 · 67 citations · 55 references
MedicineMedicinal ChemistryPharmacologyBioisosterismMolecular PharmacologyStructure-activity RelationshipsDrug-receptor InteractionsIon Channel PharmacologyLigand BindingPotency OptimizationReceptor PharmacologyReceptor-ligand InteractionsAntagonist ActivityAntagonist PotencyDrug Binding To Ion ChannelsIon Channel Structure-function RelationshipsPatch-clamp AnalysisPhenyl Ring Substitution EffectsRational DesignTransient Receptor Potential Channel Pharmacology
Adenosine 5'-diphosphoribose (ADPR) activates TRPM2, a Ca(2+), Na(+), and K(+) permeable cation channel. Activation is induced by ADPR binding to the cytosolic C-terminal NudT9-homology domain. To generate the first structure-activity relationship, systematically modified ADPR analogues were designed, synthesized, and evaluated as antagonists using patch-clamp experiments in HEK293 cells overexpressing human TRPM2. Compounds with a purine C8 substituent show antagonist activity, and an 8-phenyl substitution (8-Ph-ADPR, 5) is very effective. Modification of the terminal ribose results in a weak antagonist, whereas its removal abolishes activity. An antagonist based upon a hybrid structure, 8-phenyl-2'-deoxy-ADPR (86, IC50 = 3 μM), is more potent than 8-Ph-ADPR (5). Initial bioisosteric replacement of the pyrophosphate linkage abolishes activity, but replacement of the pyrophosphate and the terminal ribose by a sulfamate-based group leads to a weak antagonist, a lead to more drug-like analogues. 8-Ph-ADPR (5) inhibits Ca(2+) signalling and chemotaxis in human neutrophils, illustrating the potential for pharmacological intervention at TRPM2.
55
ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology
Anne‐Laure Perraud, Andrea Fleig, Christopher Dunn et al. · Nature · 2001 · 895 citations
Immunocyte Ca <sup>2+</sup> Influx System Mediated by LTRPC2
Yorikata Sano, Kohei Inamura, Akira Miyake et al. · Science · 2001 · 442 citations